1. Introduction
===============

According to an estimate, the number of diabetic people in the world would increase to around 415 million by 2025 \[[@b1-2093-6966-v22-n04-248]\]. Despite extensive research on this disease, it is necessary to find new methods for early diagnosis, treatment or prevention of complications of diabetes with the goal of improving the health of the community and reducing the cost of health care and mortality resulting from it.

In the Islamic Republic of Iran with a population of over 80 million, Diabetes is prevalent (at least 8%). As the young Iranian population grows, the incidence of diabetes will increase rapidly \[[@b2-2093-6966-v22-n04-248]\].

Glycogen Synthase Kinase 3 beta (GSK-3 beta) has been identified as the regulator of glycogen metabolism, and growth factors \[[@b3-2093-6966-v22-n04-248]\]. The PI3K / AKT pathway is activated in response to many factors including insulin and other growth factors, and the activation of this route leads to the phosphorylation and inactivation of GSK-3 beta. A major substrate of GSK-3 beta, the glycogen synthase, catalyzes the final phase of glycogen synthesis. The glycogen synthase phosphorylation by active GSK-3 beta prevents glycogen synthesis. Therefore, the deactivation of GSK-3 beta by PI3K / AKT pathway develops the storage of glucose as glycogen, which ultimately leads to a decrease in blood glucose \[[@b4-2093-6966-v22-n04-248]\].

Ras proteins are small GTPases enzymes which act as the main regulators of multiple signaling pathways. Their roles include growth control, migration, cellular connectivity, survival, and differentiation. The three types of Ras proteins include H-Ras, N-Ras, K-Ras. Ras proteins in response to growth factor or insulin activate several intracellular pathways. The K-Ras pathway activates a variety of downstream signaling molecules such as PI3K \[[@b5-2093-6966-v22-n04-248], [@b6-2093-6966-v22-n04-248]\].

Our previous serial research on the effects of *U. dioica* and L. album in diabetic rats has had interesting results (7--12), such as the modification of hepatic enzyme, the regulation of serum IGF-1 level, Cyclooxygenase-2 (Cox-2) and Caspase-3 gene expression in the liver and kidney, tracheal smooth muscle cell relaxation by Lamium album. To increase our knowledge of the functional mechanisms of these two plants, in the present study, for the first time, the effects of these two extracts on blood GSK-3 beta and K-Ras in diabetic rats were studied.

2. Materials and Methods
========================

2.1. Animals
------------

In this study, male adult Wistar rats weighing 250--350 g were used. This research was approved by the ethical committee of Guilan University of Medical Sciences **(IR. GUMS.REC.1395.222)** (Rasht, Iran).

2.2. Diabetes induction
-----------------------

This procedure performed according to the Mohseni Mehran et al. study \[[@b7-2093-6966-v22-n04-248]\]. In summary, for the induction of diabetes, Streptozotocin (STZ) was injected intraperitoneally at a dose of 60 mg / kg. Then, after 3 days (day 0), blood glucose was measured and value ≥ 300 mg/dl was considered as diabetic.

2.3. Plant material and extraction procedure
--------------------------------------------

Collection of aerial parts of two used plants and confirmation of their herbarium code were done according to our previous studies \[[@b9-2093-6966-v22-n04-248]\].

2.4. Study Design
-----------------

All 32 rats were randomly arranged into four groups, each group containing seven rats as similar to our previous work \[[@b7-2093-6966-v22-n04-248]\]. Group 1 (normal), group 2 (diabetic), group 3 diabetic treated by 100 mg/kg/28 day U. dioica and group 4 diabetic treated by 100 mg/kg/28 day L. album On the 14th and the 28th day of treatment, the weight and fasting blood sugar (FBS) was measured. Also, blood serum collected and freeze at −20 for measuring plasma levels of GSK-3 beta and K-Ras levels by Elisa method.

2.5. GSK-3 beta measurement
---------------------------

The level of serum GSK-3 beta (Total and Phosphorylated) was measured using an enzyme-linked immunosorbent assay (ELISA) kit (My Biosource, cat number MBS 7251608-96 test) and ELISA reader (Stat Fax, USA) in a single run. This kit was based on sandwiched Elisa.

2.6. K-Ras measurement
----------------------

The serum level of K-Ras was determined by using ELI-SA Kit (My Biosource, 0844859-48 strip) and ELISA reader (Stat Fax, USA) in a single run. This kit was based on standard sandwich Elisa. In brief, an antibody specific for K-Ras had been pre-coated onto a 48-well plate (12 × 4 well strips). Standards or serum samples were added to the wells, incubated. Absorbance was read at 450 nm which was quantitatively proportional to the serum level of K-Ras.

2.7. Statistical analysis
-------------------------

Data are presented as Mean ± SEM. Data distribution was evaluated by the Shapiro-Wilk test. Data were normally distributed and the groups had equal variances. One way ANOVA followed by the Tukey post hoc test was used for comparison between groups. In each group, the FBS level among different times was compared using repeated measure ANOVA. P \< 0.05 was considered as statistically significant. The analysis was done using SPSS software version 16.

3. Results
==========

3.1. Fasting blood glucose measurements
---------------------------------------

Fasting blood glucose was considerably increased in diabetic group in comparison to healthy control group (P \<0.0001). *U. dioica* extract and *L. Album* significantly decreased blood glucose levels significantly decreased blood glucose level on the 14th and 28th days in diabetic rats (P \<0.0001) ([Table 1](#t1-2093-6966-v22-n04-248){ref-type="table"}).

3.2. Measurement of GSK3 beta and K-Ras level in different groups
-----------------------------------------------------------------

The serum levels of GSK-3 beta significantly increased in diabetic group compared with healthy controls (P \< 0.0001). Both extracts reduced GSK-3 beta level, however, this reduction was only statistically significant by *U. dioica* (P \< 0.0001).

Also, the level of serum K-Ras remarkably decreased in diabetic group as compared to healthy control group (P \< 0.0001). *U. dioica* and *L. Album* significantly increased the K-Ras level in the diabetic rats (P \< 0.0001) ([Table 2](#t2-2093-6966-v22-n04-248){ref-type="table"}). No significant difference was observed in K-Ras level between diabetic rats exposed to *U. dioica* and *L. album*.

Discussion
==========

This was the first study to assess the effects of U. dioica and L. album on GSK-3 beta and K-Ras. In the present study, blood glucose level decreased in diabetic groups treated with both extracts. This finding was in agreement with Mohseni Mehran et al. \[[@b7-2093-6966-v22-n04-248]\] study that showed U. dioca and L. album could decrease blood glucose in diabetic rats. Also, Pashazadeh and Rezaei showed similar results in diabetic rats \[[@b13-2093-6966-v22-n04-248]\]. Farzami et al. and Bnouham et al. demostrated that the hypoglycemic effect of U. dioca could be due to the increase in insulin release \[[@b14-2093-6966-v22-n04-248], [@b15-2093-6966-v22-n04-248]\].

It has been shown that GSK-3 beta regulates several cellular processes. Many studies showed that GSK-3 beta level increased in diabetic rats \[[@b16-2093-6966-v22-n04-248], [@b17-2093-6966-v22-n04-248]\]. In the present study, the GSK-3 Beta elevated in diabetic groups, but both extracts decreased its level. Also, U. dioica and *L. album* decreased blood glucose level in diabetic rats indicating their ability to ameliorate blood glucose metabolism potentially with GSK3 inhibition. Yu et al. reported that GLUT4 and GSK3β (downstream of PI3K) are the important proteins in controlling glucose uptake and storage and glycogen metabolism \[[@b19-2093-6966-v22-n04-248]\]. Therefore, the drugs regulating the above proteins could be promising in the treatment of Diabetes. U. dioica and L. album demonstrated to be effective in controlling high glucose and relieving the symptoms of DM patients. Previously, we found that U. dioica and L. album could decrease both serum glucose and lipid levels in STZ-induced diabetic rats \[[@b7-2093-6966-v22-n04-248]\]. However, the molecular mechanisms of these herbs still need to be explored. Hence, we showed the effect of U. dioica and L. album on diabetes condition by impacting on GSK-3 beta and its association with PI3K/Akt signaling pathway.

As mentioned earlier, RAS proteins activate several intracellular pathways in response to growth factor or insulin. In this study, the serum level of K-Ras significantly decreased in diabetic group compared to control group. *U. dioica* and *L. Album* extracts significantly increased the enzyme level in diabetic rats. Our finding was in line with the result of Cline et al. that showed treatment with GSK-3 inhibitor lowered fasting hyperglycemia in diabetic rats; this study suggested that GSK-3 inhibition may represent an important new therapeutic target for the treatment of patients with diabetes \[[@b18-2093-6966-v22-n04-248]\].

Conclusion
==========

It was found that the hypoglycemic properties demonstrated by *U. dioica* and *L. album* might be partly due to the decrease in GSK-3 beta and increase in K-Ras levels, although the involved molecular mechanisms need to be further examined.
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###### 

The blood glucose level in studied groups.

  Groups        Day 0                                                           Day 14                                                          Day 28
  ------------- --------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  Control       112±9[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}     89±6[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}      106±7[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}
  Diabetic      530± 12[\#](#tfn2-2093-6966-v22-n04-248){ref-type="table-fn"}   515± 7[\#](#tfn2-2093-6966-v22-n04-248){ref-type="table-fn"}    499±11[\#](#tfn2-2093-6966-v22-n04-248){ref-type="table-fn"}
  *U. dioica*   390±15[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}    255±8[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}     211±4.5[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}
  *L. album*    422±13[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}    220±7.5[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}   200±5[\*](#tfn3-2093-6966-v22-n04-248){ref-type="table-fn"}

Values are presented as Mean±SEM.

P \< 0.0001 by comparison with control rats.

P \< 0.0001 by comparison with diabetic rats.

###### 

Effect of *U. dioica* and *L. album* on Serum level of GSK-3 beta and K-Ras

  Groups        GSK-3 beta                                                        K-Ras
  ------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  Control       2.68±0.60[\*](#tfn6-2093-6966-v22-n04-248){ref-type="table-fn"}   2.86±0.07[\*](#tfn6-2093-6966-v22-n04-248){ref-type="table-fn"}
  Diabetic      6.30±2.17[\#](#tfn5-2093-6966-v22-n04-248){ref-type="table-fn"}   2.57±0.04[\#](#tfn5-2093-6966-v22-n04-248){ref-type="table-fn"}
  *U. dioica*   2.75±0.82[\*](#tfn6-2093-6966-v22-n04-248){ref-type="table-fn"}   2.88±0.05[\*](#tfn6-2093-6966-v22-n04-248){ref-type="table-fn"}
  *L album*     3.56±0.28[\#](#tfn5-2093-6966-v22-n04-248){ref-type="table-fn"}   2.78±0.02[\*](#tfn6-2093-6966-v22-n04-248){ref-type="table-fn"}

Values are presented as Mean±SEM.

P \< 0.0001 by comparison with control rats.

P \< 0.0001 by comparison with diabetic rats.
